chain, CD11c, and CD103, without expressing CD25 and CD123 that are usually identified in cHCL ( Figure 1C) . The lymphoid cells were also detected in the bronchoalveolar lavage fluid. The karyotype of the peripheral blood lymphocytes showed a 7q deletion in position 22-36, a recurrent but unspecific abnormality in vHCL. The BRAF V600E mutation was not present, confirmed by high-throughput sequencing. A mutation in the KDM6A gene, encoding a protein implicated in epigenetics, as well as a subclonal mutation of the MAP2K1 gene, was identified. 6 The allelic frequency of this last mutation increased over time. Three months after diagnosis, treatment with cladribine (0.14 mg/kg SC J1-J5) combined with rituximab (375 mg/m 2 IV on day 1) was started. The treatment was not effective, and a second-line treatment with moxetumomab pasudotox, an anti-CD22 antibody coupled to an immunotoxin, was started according to a schedule of administration on D1, D3, D5 every 28 days for six cycles (2.9 mg IV). The treatment was again not effective. A splenectomy was performed: the spleen histological examination showed a massive lymphoid infiltration with CD20 and Bcl2 positive cells, expansion of the red pulp and disappearance of the white splenic pulp. All these features are compatible with vHCL diagnosis. Splenectomy allowed the normalization of hemoglobin and platelet counts. Lymphocytosis remained stable approximately 50 × 10 9 /L. After 18 months, the patient progressed, with an increase in dyspnoea that required oxygen therapy. The hemogram showed anemia at 6.6 g/dL and thrombocytopenia at 10 × 10 9 /L. Treatment with ibrutinib at a dose of 420 mg per day was started. Four months later, oxygen therapy was stopped; at this time, cytopenias were 
| CASE 2
Hairy cell leukemia was diagnosed in a 72-year-old male with no particular antecedent. There was bone marrow infiltration (15%) by lymphoid cells expressing B-cell markers CD19, FMC7, CD20, and CD79b, as well as a monotypic kappa light chain and the CD11c and CD103 without expressing CD25 and CD123 ( Figure 2C ). One year after diagnosis, treatment with cladribine for 5 days was started, but the splenomegaly remained bulky. The hemogram showed a moderate anemia (11.7 g/dL), thrombocytopenia Sequencing of the variable part of the immunoglobulin heavy chains showed a non-mutated IGHV profile VH4-34.
| DISCUSSION
The presence of hairy cells in a blood smear could suggest a diagnosis of cHCL, vHCL, SMZL, or SDRPL. 5 The differences between the four entities are summarized in Table 1 .
Patients with cHCL have a lower mean age at diagnosis and often have pancytopenia associated with monocytopenia. In cHCL, the villi are not polar, and the nucleoli are not or barely visible. The BRAF V600E mutation is present in more than 80% of cases. 7 In most cases, patients with vHCL have hyperlymphocytosis with hairy cells with a clearly defined nucleus. 8 The BRAF V600E mutation is absent and MAP2K1 gene mutations are observed in one-third of the cases. 3 In SMZL, In both patients, we retained the diagnosis of vHCL. Splenomegaly, present in both patients, is observed in 85% of cases of vHCL. The pulmonary involvement with appearance of cystic interstitial pneumonitis of the first patient may be associated with vHCL, no other cause having been found. The association between interstitial pneumonitis and hairy cell leukemia was not reported in the literature. The morphology of the lymphocytes in these two patients suggests the diagnosis of vHCL, particularly the presence of a net nucleolus and fine and circumferential villi. Both patients had cytopenias and one of them had significant hyperlymphocytosis. The HCL score at 2 is also consistent with this diagnosis. Splenic histological examination also excludes the diagnosis of SMZL. The absence of a BRAF V600E mutation in both patients and the presence of a MAP2K1 mutation in the first patient are arguments in favor of the diagnosis of vHCL. Mutations of KDM6A have not been described in SDRPL and SMZL. Given the small number of patients, treatment of vHCL is not yet established. 17 Purine analogs in monotherapy are not very effective and the first line is often based on the use of purines analogs associated with rituximab. This association was not effective in the first patient who also failed to respond to moxetumomab pasudotox, a new treatment under evaluation. 18 By contrast, in both patients, splenectomy allowed symptom relief and improved the cytopenias. In the first case, the patient also benefited from ibrutinib. Ibrutinib, an orally available Bruton tyrosine kinase inhibitor (BTK), plays a central role in B-cell receptor signaling and impacts homing and adhesion of B cells. 19 Clinical studies on the use of ibrutinib in various non-Hodgkin's malignant B-cell lymphomas have shown encouraging results, particularly in chronic lymphocytic leukemia and mantle cell lymphoma. 20 In vitro studies on HCL have shown that ibrutinib inhibits the survival and proliferation of hairy cells. 21 A phase II trial is evaluating the use of ibrutinib in patients with relapsed cHCL and vHCL. Preliminary results are encouraging, with partial responses in vHCL with little toxicity after a median followup of 22 months. 22 After a follow-up of 4 months, patient 1 was greatly improved by this treatment.
| CONCLUSION
In the age of personalized medicine and increasing treatment choices, it is important to perform an accurate diagnosis to support the patient optimally. The number of cases of vHCL reported in the literature is still low because of the rarity of this hematologic disorder. These two clinical cases illustrate patient profiles that physicians may face in their daily practice. The first patient's profile is that of an aggressive and multiply refractory disease, and the second is of a more indolent disease that responded very well to splenectomy. The two cases represent the heterogeneity of vHCL in terms of clinical presentation as well as management. Despite a short follow-up period in the case of the first patient, the initial response to treatment remains satisfactory. These cases further underscore that the therapeutic armamentarium for vCHL could be diverse, ranging from ibrutinib to splenectomy.
